Published in Br J Cancer on June 01, 1991
Clinical validation of an autoantibody test for lung cancer. Ann Oncol (2010) 1.55
Differential expression of carbohydrate antigen 19-9 in human colorectal cancer: A comparison with colon and rectal cancers. Mol Clin Oncol (2013) 0.76
Colorectal carcinoma with extremely low CA19-9. Gastroenterol Res Pract (2009) 0.75
Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet (1979) 7.28
Randomised, controlled trial of faecal occult blood screening for colorectal cancer. Results for first 107,349 subjects. Lancet (1989) 4.72
Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem (1983) 3.91
Specific antigen in serum of patients with colon carcinoma. Science (1981) 3.68
Repeated screening for colorectal cancer with fecal occult blood test. A prospective randomized study at Funen, Denmark. Scand J Gastroenterol (1989) 2.03
Comparison of CA 19-9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases. Br J Cancer (1984) 1.56
Monoclonal antibody detection of a circulating tumor-associated antigen. II. A longitudinal evaluation of patients with colorectal cancer. J Clin Immunol (1982) 1.31
Delay in diagnosis and treatment of symptomatic colorectal cancer. Lancet (1979) 4.91
Relation between house-dust endotoxin exposure, type 1 T-cell development, and allergen sensitisation in infants at high risk of asthma. Lancet (2000) 4.19
A classification of fistula-in-ano. Br J Surg (1976) 4.09
Blocking of lymphocyte-mediated cytotoxicity for rat hepatoma cells by tumour-specific antigen-antibody complexes. Nat New Biol (1972) 4.04
Controlled trial of faecal occult blood testing in the detection of colorectal cancer. Lancet (1983) 3.99
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol (2000) 3.33
Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut (1988) 3.14
Clinicopathological staging for colorectal cancer: an International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT). J Gastroenterol Hepatol (1991) 2.83
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer (2001) 2.58
The risks of screening: data from the Nottingham randomised controlled trial of faecal occult blood screening for colorectal cancer. Gut (1999) 2.53
Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut (2002) 2.50
Surgical emergencies and manpower. Ann R Coll Surg Engl (1984) 2.48
Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology (2002) 2.35
Study of large bowel peristalsis. Gut (1968) 2.34
A phase I/II study of trichosanthin treatment of HIV disease. AIDS (1990) 2.26
The influence of tumour cell DNA abnormalities on survival in colorectal cancer. Br J Surg (1985) 2.20
A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol (1995) 2.20
Ambulatory monitoring of oesophageal pH in reflux oesophagitis using a portable radiotelemetry system. Gut (1982) 2.19
Taurolidine peritoneal lavage as prophylaxis against infection after elective colorectal surgery. Br J Surg (1994) 2.18
The results of 1115 patients with colorectal cancer treated over an 8-year period in a single hospital. Eur J Surg Oncol (1985) 2.03
Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer (1989) 1.97
Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol (2006) 1.97
Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut (1992) 1.96
Onset and persistence of childhood asthma: predictors from infancy. Pediatrics (2001) 1.91
Long-term results with the Kasai operation for biliary atresia. Arch Surg (1996) 1.90
Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res (1990) 1.85
Screening interval breast cancers: mammographic features and prognosis factors. Radiology (1996) 1.82
Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer (2005) 1.75
Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax (2007) 1.73
Radioimmunodetection of human colorectal cancers by an anti-tumour monoclonal antibody. Lancet (1982) 1.71
Ki-ras mutations in adenomas: a characteristic of cancer-bearing colorectal mucosa. J Pathol (1996) 1.70
Cost-effective screening strategies for colorectal cancer. J Public Health Med (1992) 1.67
Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut (2011) 1.67
Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer (2001) 1.65
Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res (1999) 1.65
Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer (1995) 1.60
Clinical and economic consequences of wound sepsis after appendicectomy and their modification by metronidazole or povidone iodine. Lancet (1981) 1.57
Physical factors in the stimulation of colonic peristalsis. Gut (1970) 1.57
Early-onset breast cancer--histopathological and prognostic considerations. Br J Cancer (1997) 1.56
Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br J Cancer (2001) 1.56
Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer. Ann Oncol (1995) 1.53
Factors affecting compliance with screening for colorectal cancer. Community Med (1984) 1.52
Faecal occult blood screening for colorectal cancer: is it cost-effective? Health Econ (1998) 1.51
Respiratory mucins: identification of core proteins and glycoforms. Biochem J (1996) 1.50
Inhibition of hepatoma-immune lymph-node cell cytotoxicity by tumour-bearer serum, and solubilized hepatoma antigen. Int J Cancer (1973) 1.49
Screening for colorectal cancer with an immunological faecal occult blood test: 2-year follow-up. Br J Surg (1996) 1.49
Screening for symptomless colorectal cancer by testing for occult blood in general practice. Lancet (1980) 1.48
Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. J Pathol (1999) 1.47
Clinical and radiographic features of simple and hydatid cysts of the liver. Br J Surg (1986) 1.47
A frequency-duration index (FDI) for the evaluation of ambulatory recordings of gastro-oesophageal reflux. Br J Surg (1984) 1.45
C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer (1996) 1.44
Bile reflux in columnar-lined Barrett's oesophagus. Ann R Coll Surg Engl (1993) 1.44
Screening and the costs of treating colorectal cancer. Br J Cancer (1993) 1.44
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res (1994) 1.43
Acute non-tuberculous psoas abscess. Report of 10 cases and review of the literature. Br J Surg (1970) 1.42
The 1983 distribution of hospitals and hospital beds in the RSA by area, race, ownership and type. S Afr Med J (1990) 1.41
Extent of ductal carcinoma in situ within and surrounding invasive primary breast carcinoma. Br J Surg (2001) 1.41
Fecal occult blood screening for colorectal cancer in the general population. Results of a controlled trial. Cancer (1986) 1.40
Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer (1995) 1.40
Flexible fiberoptic sigmoidoscopy and double-contrast barium-enema examination in the identification of adenomas and carcinoma of the colon. Dis Colon Rectum (1983) 1.39
Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev (2000) 1.39
Assessment of angiogenesis in breast carcinoma: an important factor in prognosis? Hum Pathol (1995) 1.39
Predeposit autologous blood transfusion in patients with colorectal cancer: a feasibility study. Br J Surg (1992) 1.39
Control theory, labeling theory, and the delivery of services for drug abuse to adolescents. Adolescence (1997) 1.38
c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer (1991) 1.37
Early diagnosis of colorectal cancer: a review. J R Soc Med (1984) 1.37
Isolation of a variant of Candida albicans. Infect Immun (1982) 1.34
Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival. Eur J Surg Oncol (1995) 1.34
Metropolitan home living conditions associated with indoor endotoxin levels. J Allergy Clin Immunol (2001) 1.33
Subcuticular suturing after appendicectomy. Lancet (1977) 1.32
c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene (1998) 1.30
Interval cancers in a randomized controlled trial of screening for colorectal cancer using a faecal occult blood test. Int J Epidemiol (1999) 1.29
An evaluation of flexible fibreoptic sigmoidoscopy. Br Med J (Clin Res Ed) (1981) 1.28
Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res (1995) 1.27
Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat (1994) 1.27
Diagnosis of breast cancer with core-biopsy and fine needle aspiration cytology. Aust N Z J Surg (1996) 1.26
INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res (2000) 1.26
Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer (1994) 1.25
Gastrointestinal intraluminal pH in normal subjects and those with colorectal adenoma or carcinoma. Gut (1990) 1.22
The action of sennosides and related compounds on human colon and rectum. Gut (1970) 1.22
Airborne dust, ammonia, microorganisms, and antigens in pig confinement houses and the respiratory health of exposed farm workers. Am Ind Hyg Assoc J (1991) 1.22
Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer (1993) 1.22
Comparison of rigid and flexible fibreoptic sigmoidoscopy with double contrast barium enemas. Br J Surg (1982) 1.21
Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening. Br J Surg (1997) 1.21
Immunogenic properties of rat hepatoma subcellular fractions. Br J Cancer (1974) 1.20
Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer (1999) 1.20
Bleeding patterns in colorectal cancer: the effect of aspirin and the implications for faecal occult blood testing. Br J Surg (1982) 1.20
An immunohistochemical examination of the expression of E-cadherin, alpha- and beta/gamma-catenins, and alpha2- and beta1-integrins in invasive breast cancer. J Pathol (1999) 1.20
Embryonic antigen expression on experimental rat tumours. Transplant Rev (1974) 1.20
Assessment of proliferation of squamous, Barrett's and gastric mucosa in patients with columnar lined Barrett's oesophagus. Gut (1992) 1.20
Accuracy of occult blood tests over a six-day period. Clin Oncol (1983) 1.19
Colorectal screening by a self-completion questionnaire. Gut (1984) 1.19
A comparison of an immunological faecal occult blood test Fecatwin sensitive/FECA EIA with Haemoccult in population screening for colorectal cancer. Br J Cancer (1985) 1.19
Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36. Immunology (1989) 1.18
Objective measurement of therapeutic response in breast cancer using tumour markers. Br J Cancer (1991) 1.18
Colorectal cancer, screening and survival: the influence of socio-economic deprivation. Public Health (2003) 1.18
Detection of circulating hepatoma D23 antigen and immune complexes in tumour bearer serum. Br J Cancer (1973) 1.17